Using CRISPR/Cas9, scientists identified RBM5 as a vital component of leukemia cell fitness, making it a promising target for drug development. The protein HOXA9 is overexpressed in most acute myeloid ...
In biotechnology, timing is everything. Whether advancing a novel therapy or scaling a platform, companies often reach a pivotal point: go public or sell. Increasingly, biotech executives are choosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results